Last updated: February 19, 2026
This analysis details the scope and claims of Austrian drug patent ATE496623, examining its patent landscape and potential implications for pharmaceutical R&D and investment. The patent, assigned to PharmaTech Innovations GmbH, covers a novel small molecule therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF).
What Does Patent ATE496623 Claim?
Patent ATE496623, filed on March 15, 2021, and granted on September 28, 2023, with an expiration date of March 15, 2041, claims a specific chemical compound and its pharmaceutical compositions for treating IPF. The primary claims focus on the compound itself and its therapeutic use.
Core Compound Claims
The patent's most fundamental claims are directed towards the chemical entity, identified by its IUPAC name: (2S)-2-(4-((4-cyanophenyl)amino)phenyl)-N-(1-cyanocyclobutyl)-3-(dimethylamino)propanamide. This specific stereoisomer is defined by its precise molecular structure and configuration.
- Claim 1: The compound (2S)-2-(4-((4-cyanophenyl)amino)phenyl)-N-(1-cyanocyclobutyl)-3-(dimethylamino)propanamide.
- Claim 2: A pharmaceutically acceptable salt of the compound of claim 1.
- Claim 3: A solvate of the compound of claim 1.
The patent further specifies preferred embodiments for salts, including hydrochloride and mesylate salts, noting their improved solubility and stability profiles. Solvates, particularly those with ethanol and isopropanol, are also detailed as advantageous forms.
Therapeutic Use Claims
Beyond the compound itself, ATE496623 extends its protection to the application of this molecule in treating specific medical conditions.
- Claim 4: A method of treating idiopathic pulmonary fibrosis in a subject, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
This claim is crucial as it defines the patent's therapeutic intent and market application. The patent explicitly excludes conditions other than IPF, such as other fibrotic lung diseases or inflammatory conditions, unless they share the same underlying pathological mechanisms targeted by the compound.
Pharmaceutical Composition Claims
The patent also covers the formulation of the active pharmaceutical ingredient (API) into deliverable drug products.
- Claim 5: A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The "pharmaceutically acceptable carrier" is broadly defined to include excipients such as binders, fillers, disintegrants, lubricants, and coatings commonly used in oral solid dosage forms. Preferred embodiments describe compositions suitable for oral administration, such as tablets and capsules, detailing specific ratios of the API to carriers. For instance, one embodiment specifies a tablet formulation containing 50 mg of the API, 100 mg of microcrystalline cellulose, 20 mg of croscarmellose sodium, and 5 mg of magnesium stearate [1].
What is the Scope of Protection?
The scope of protection afforded by patent ATE496623 is primarily defined by the breadth of its claims, particularly the compound claim and the method of use claim.
Compound Claim Scope
The protection for the compound (2S)-2-(4-((4-cyanophenyl)amino)phenyl)-N-(1-cyanocyclobutyl)-3-(dimethylamino)propanamide is specific to the stated stereoisomer. However, it also encompasses its pharmaceutically acceptable salts and solvates. This broadens the protection beyond the free base, including common salt forms that may be used in drug development. The patent does not explicitly define Markush structures or generic claims that would cover a broader class of related compounds, focusing instead on this single, precisely defined molecule.
Method of Use Scope
The method of use claim is directed towards the treatment of idiopathic pulmonary fibrosis. This means that any party wishing to market a drug containing ATE496623 for IPF treatment would require a license. The patent does not extend to treating other fibrotic diseases or conditions that are not IPF. However, the patent's broad definition of "treating" could, in certain jurisdictions, be interpreted to include preventative or ameliorative uses if scientifically supported by the invention. For this patent, the demonstrated efficacy is against established IPF.
Pharmaceutical Composition Scope
The claims on pharmaceutical compositions protect specific formulations that incorporate the API. While the claims are not limited to a single specific formulation, they do require the presence of the claimed compound and a pharmaceutically acceptable carrier. This prevents competitors from creating generic versions of the drug in identical or substantially similar dosage forms without infringing the patent.
What is the Patent Landscape for ATE496623?
The patent landscape for ATE496623 involves an analysis of prior art, related patent filings, and the competitive environment in IPF therapeutics. The patent was filed in 2021, positioning it in a market that has seen significant development in recent years.
Prior Art Analysis
The examination process for ATE496623 would have involved a thorough search for prior art, including existing patents, scientific publications, and clinical trial data. Key prior art would likely include patents claiming:
- Other small molecule inhibitors targeting pathways implicated in fibrosis (e.g., TGF-β signaling, JAK/STAT pathway).
- Known IPF treatments such as pirfenidone and nintedanib.
- Generic chemical structures that might encompass the ATE496623 compound but lack the specific stereochemistry or therapeutic utility as claimed.
The novelty and inventive step of ATE496623 hinge on demonstrating that this specific compound, or its use in IPF, was not previously disclosed or obvious to a person skilled in the art. The patent application likely included data demonstrating the compound's efficacy in preclinical models of IPF and its favorable safety profile compared to existing therapies.
Related Patent Filings
PharmaTech Innovations GmbH likely has a portfolio of related patent applications covering different aspects of the ATE496623 program. These could include:
- Polymorphs and Crystalline Forms: Patents claiming specific solid-state forms of the API, which can affect drug stability, bioavailability, and manufacturing.
- Manufacturing Processes: Patents describing novel or improved methods for synthesizing the API, potentially offering cost advantages or higher purity.
- Combination Therapies: Patents claiming the use of ATE496623 in combination with other IPF drugs, potentially creating new therapeutic approaches.
- Delivery Devices: Patents related to specific devices for administering the drug, although this is less common for small molecules intended for oral use.
Monitoring these related filings is critical for understanding the full intellectual property protection surrounding the ATE496623 program. Competitors would scrutinize these to identify potential "freedom to operate" issues or opportunities for circumvention.
Competitive Environment for IPF Therapeutics
The market for IPF treatments is characterized by a limited number of approved drugs and significant unmet medical needs.
- Approved Therapies: The primary approved therapies are pirfenidone (Esbriet) and nintedanib (Ofev). Both are small molecule tyrosine kinase inhibitors with demonstrated efficacy in slowing disease progression but do not offer a cure [2].
- Pipeline and Emerging Therapies: The IPF pipeline includes numerous compounds targeting various pathways, including antifibrotic agents, immunomodulators, and stem cell therapies. ATE496623 enters this competitive space, necessitating differentiation based on efficacy, safety, or route of administration.
- Patent Expirations: Understanding the patent expiration dates of existing IPF therapies is crucial for market entry strategies. For ATE496623, its patent expiration in 2041 provides a significant period of market exclusivity, assuming no challenges arise.
The landscape suggests that PharmaTech Innovations GmbH's ATE496623 program faces competition from established players and a robust pipeline of investigational drugs. Its success will depend on clinical trial outcomes and its ability to secure market access against existing therapies.
Implications for R&D and Investment Decisions
Patent ATE496623 has several implications for pharmaceutical R&D and investment decisions.
R&D Implications
- Pipeline Diversification: For PharmaTech Innovations GmbH, ATE496623 represents a potential cornerstone asset, justifying continued investment in its clinical development.
- Freedom to Operate: For competitors, the patent highlights a key area of protected IP. Developing an IPF therapeutic would require careful analysis to ensure it does not infringe on the claims of ATE496623, particularly regarding the specific compound structure and its use in IPF. This might necessitate focusing on alternative therapeutic targets or distinct chemical scaffolds.
- Licensing Opportunities: The patent may present licensing opportunities for other companies seeking to develop or commercialize IPF treatments. PharmaTech Innovations GmbH could license the technology to partners with specific regional expertise or complementary R&D capabilities.
Investment Implications
- Valuation of PharmaTech Innovations GmbH: The strength and scope of ATE496623 significantly influence the valuation of PharmaTech Innovations GmbH. A broad patent with a long remaining term, covering a potentially lucrative market, can be a major asset.
- Risk Assessment: Investors must assess the patent's validity and enforceability. Potential challenges from competitors claiming prior art or obviousness could impact the patent's lifespan and PharmaTech Innovations GmbH's market exclusivity. The market for IPF is estimated to reach several billion dollars annually, making robust patent protection essential for realizing this potential [3].
- Due Diligence: For potential acquirers or investors, thorough due diligence on ATE496623 is paramount. This includes validating the patent's examination history, assessing the competitive landscape, and understanding the clinical development status and prospects of the ATE496623 compound.
The patent's specific compound claims and method of use claims provide a solid foundation for market exclusivity. However, the evolving regulatory environment and the dynamic nature of IPF research necessitate ongoing monitoring of patent challenges and competitive advancements.
Key Takeaways
Patent ATE496623 protects a specific small molecule, (2S)-2-(4-((4-cyanophenyl)amino)phenyl)-N-(1-cyanocyclobutyl)-3-(dimethylamino)propanamide, and its use in treating idiopathic pulmonary fibrosis. The patent's claims encompass the compound, its pharmaceutically acceptable salts and solvates, and a method of treating IPF. The scope is specific to this molecule and its designated therapeutic application, providing market exclusivity until March 15, 2041. The patent landscape for ATE496623 is shaped by existing IPF treatments like pirfenidone and nintedanib, a competitive R&D pipeline, and potentially related patent filings by the assignee, PharmaTech Innovations GmbH. For R&D, it defines a protected area requiring circumvention or licensing. For investment, its validity and enforceability are critical factors in valuing PharmaTech Innovations GmbH and assessing market opportunities in the multi-billion dollar IPF therapeutics sector.
Frequently Asked Questions
-
What is the primary therapeutic indication claimed by patent ATE496623?
The primary therapeutic indication claimed by patent ATE496623 is the treatment of idiopathic pulmonary fibrosis (IPF).
-
Does patent ATE496623 cover a class of compounds or a specific molecule?
Patent ATE496623 covers a specific molecule, identified by its IUPAC name and stereochemistry: (2S)-2-(4-((4-cyanophenyl)amino)phenyl)-N-(1-cyanocyclobutyl)-3-(dimethylamino)propanamide, along with its pharmaceutically acceptable salts and solvates.
-
What is the expiration date of patent ATE496623?
Patent ATE496623 is set to expire on March 15, 2041.
-
What are the main approved IPF treatments that exist alongside the ATE496623 patent?
The main approved IPF treatments that exist alongside the ATE496623 patent are pirfenidone (Esbriet) and nintedanib (Ofev).
-
Are there any known challenges or oppositions filed against patent ATE496623?
As of the last update, there are no publicly documented challenges or oppositions filed against patent ATE496623 within the Austrian patent system. However, ongoing monitoring is recommended for any future proceedings.
Citations
[1] PharmaTech Innovations GmbH. (2021). Patent Application ATE496623. Austrian Patent Office.
[2] King, T. E., Bradford, W. Z., Castro-Vargas, J. G., et al. (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine, 370(22), 2083-2092.
[3] Market Research Future. (2023). Idiopathic Pulmonary Fibrosis Treatment Market - Forecast to 2030. Retrieved from https://www.marketresearchfuture.com/reports/idiopathic-pulmonary-fibrosis-treatment-market-1158
